Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
06 Gennaio 2025 - 1:00PM
Immunocore to present at the 43rd Annual J.P.
Morgan Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings
plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a
commercial-stage biotechnology company pioneering and delivering
transformative immunomodulating medicines to radically improve
outcomes for patients with cancer, infectious diseases and
autoimmune diseases, today announced that management will
participate in in a presentation at the 43rd Annual J.P. Morgan
Healthcare Conference in San Francisco, California.
The presentation is scheduled for Wednesday,
January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST).
The presentation will be webcast live and can be
accessed by visiting ‘Events & Presentations’, under ‘Events’,
via the ‘Investors’ section of Immunocore’s website at
www.immunocore.com. Following the event, a replay of the
presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of CommunicationsT: +44
(0) 7458030732E: sebastien.desprez@immunocore.comFollow on Twitter:
@Immunocore
Investor Relations
Clayton Robertson, Head of Investor RelationsT:
+1 (215) 384-4781E: ir@immunocore.com
Grafico Azioni Immunocore (NASDAQ:IMCR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Immunocore (NASDAQ:IMCR)
Storico
Da Gen 2024 a Gen 2025
